Mediwound Receives Buy Rating Due to EscharEx's Market Potential
Michael Okunewitch, an analyst from Maxim Group, has maintained a Buy rating on Mediwound (MDWD), with the price target remaining at $30.00. This optimistic outlook is largely due to the potential of EscharEx, a product designed to meet the unmet needs in chronic wound care. EscharEx is supported by a well-designed Phase 3 study for venous leg ulcers and a planned study for diabetic foot ulcers. Mediwound anticipates that EscharEx will capture a significant market share by offering a unique combination of the speed and effectiveness of surgical debridement and the tolerability of non-invasive methods.
Mediwound's market analysis indicates a substantial opportunity for EscharEx, with a projected $2.5 billion market across diabetic foot ulcers and venous leg ulcers. This projection is based on the product's competitive pricing and superior attributes compared to existing options. EscharEx is expected to play a disruptive role in chronic wound care, positioning Mediwound for significant growth in the enzymatic debridement market.
In addition to Maxim Group's endorsement, Citi also maintained a Buy rating on Mediwound's stock with a $25.00 price target. Despite a moderate price drop over the past six months, from $18.970 to $16.720, the outlook for Mediwound remains positive due to the potential impact of EscharEx in the chronic wound care market.
MediWound Ltd., founded in 2001 by Lior Rosenberg and Marian Gorecki and headquartered in Yavne, Israel, is a biopharmaceutical company focused on developing, manufacturing, and commercializing products for severe burns, chronic wounds, and other hard-to-heal wounds, with NexoBrid being one of its key products.